MARKET

TLGT

TLGT

Teligent Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.5657
+0.0218
+4.01%
After Hours: 0.5511 -0.0146 -2.58% 18:39 11/23 EST
OPEN
0.5841
PREV CLOSE
0.5439
HIGH
0.5900
LOW
0.5450
VOLUME
2.52M
TURNOVER
--
52 WEEK HIGH
6.90
52 WEEK LOW
0.4550
MARKET CAP
3.05M
P/E (TTM)
-0.0574
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
ALGN, AHT, NVIV and TMBR among midday movers
Gainers: Ever-Glory International (EVK) +300%.Sequential Brands (SQBG) +106%.TuanChe (TC) +58%.Hexindai (HX) +34%.Align Technology (ALGN) +33%.KBS Fashion (KBSF) +27%.Ashford Hospitality Trust (AHT) +24%.Bio-Path (BPTH) +21%.First Internet Bancorp (INBK) +20%.LMP Automotive (LMPX) +18%.Losers: InVivo Therapeutics  (NVIV) -45%.Insignia
Seekingalpha · 10/22 16:38
Teligent, Inc. Announces Adjournment of Special Meeting of Stockholders
Scheduled to Reconvene on November 11, 2020 Company Urgently Encourages Stockholders to VoteBUENA, N.J., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Teligent, Inc. (Nasdaq: TLGT), a New Jersey-based specialty generic pharmaceutical company (the “Company”), announced today that its Special Meeting of Stockholders, scheduled for October 22, 2020, was convened and adjourned without any business being conducted due to the fact that a quorum was not achieved on the proposals to be approved. Stockholders have thus far strongly supported the proposals. At the time the meeting was convened, approximately 93.8% of the shares that had been voted had been voted in favor of the proposals. However, since holders of only 36.7% of the outstanding shares submitted proxies to vote, the necessary quorum of a majority of the outstanding shares was not reached. The Company is adjourning the meeting in order to solicit additional votes to meet the quorum requirement.The Special Meeting will be reconvened at 10:00 a.m. Eastern time on November 11, 2020 to allow more opportunity for stockholders to vote on the proposals described in the Company’s definitive proxy statement filed with the Securities and Exchange Commission (the “SEC”) on September 9, 2020. Stockholders will be able to attend the rescheduled Special Meeting virtually by visiting www.virtualshareholdermeeting.com/TLGT2020SM.The record date for determining stockholders eligible to vote on the proposals at the Special Meeting remains September 4, 2020.The Company strongly encourages any eligible stockholder that has not yet voted their shares, or provided voting instructions to their broker or other record holder, to do so promptly. No action is required by any stockholder who has previously delivered a proxy and who does not wish to revoke or change that proxy. Shares may be voted via the Internet, by telephone and by mail. For questions relating to the voting of shares or to request additional or misplaced proxy voting materials, contact the Company’s proxy solicitor: MacKenzie Partners, Inc. TOLL‐FREE, at 1‐800-322-2885 or COLLECT at 1-212-929-5500 or via email at proxy@mackenziepartners.com.YOUR PARTICIPATION IS IMPORTANT – PLEASE VOTE TODAYA copy of the Company’s proxy statement as previously filed with the SEC is available at no charge on the SEC website at www.sec.gov. In addition, copies of the proxy statement and other documents may be obtained free of charge by accessing the Company’s website at www.teligent.com or by contacting the Company’s Corporate Secretary at (856) 776-4632, via email at InvestorsRelations@teligent.com or by mail to Corporate Secretary, Teligent, Inc., 105 Lincoln Avenue, Buena, NJ 08310.Additional InformationThis communication may be deemed to be solicitation material. On September 9, 2020, the Company filed a definitive proxy statement with the SEC in connection with the Special Meeting. STOCKHOLDERS ARE URGED TO READ CAREFULLY AND IN THEIR ENTIRETY THE PROXY STATEMENT AND ANY OTHER SOLICITING MATERIALS THAT ARE FILED WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THESE DOCUMENTS CONTAIN IMPORTANT INFORMATION ABOUT THE COMPANY AND THE PROPOSALS TO BE VOTED UPON. The Company’s proxy statement and any other solicitation materials filed by the Company with the SEC can be obtained free of charge at the SEC’s website at www.sec.gov and at the investor relations section of the Company’s website at www.teligent.com. The Company, its directors and certain of its officers and employees will be participants in the solicitation of proxies from stockholders in respect of the Special Meeting. The Company has also engaged MacKenzie Partners to aid in the solicitation of proxies. Detailed information regarding the identity of the participants, and their respective interests in the Company by security holdings or otherwise, are set forth in the definitive proxy statement for the Special Meeting. The contents of the websites referenced above are not deemed to be incorporated by reference into the proxy statement.Forward-Looking Statements This press release includes “forward-looking statements” that are intended to qualify for the safe harbors from liability provided by Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts are statements that could be deemed forward-looking. These statements are based on current expectations, estimates, forecasts and projections about the Company’s business and the industry in which the Company operates and the beliefs and assumptions of the Company’s management. Forward-looking statements can be identified by the use of words such as “will,” “may,” “could,” “should,” “would,” “believe,” “depends,” “expect,” “goal,” “anticipate,” “forecast,” “project,” “future,” “intend,” “plan,” “estimate,” “target,” “indicate,” “outlook,” and similar expressions of future intent or the negative of such terms. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, these forward-looking statements are based on management’s current beliefs, expectations and assumptions and are subject to risks and uncertainties. These statements are based on the Company’s current beliefs or expectations and are inherently subject to various risks and uncertainties, including those set forth under the caption “Risk Factors” in the Company’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other periodic reports the Company files with the Securities and Exchange Commission. Additionally, many of these risks and uncertainties are currently amplified by and will continue to be amplified by, or in the future may be amplified by, the COVID-19 outbreak and the effects thereof on the Company’s future performance and results of operations. It is not possible to predict or identify all such risks. There may be additional risks that the Company considers immaterial or which are unknown. You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements included in this press release speak only as of the date hereof and, subject to any continuing obligations under applicable law or any relevant stock exchange rules, we expressly disclaim any obligation to disseminate, after the date of this document, any updates or revisions to any such forward-looking statements to reflect any change in expectations or events, conditions or circumstances on which any such statements are based.Contact: Philip K. Yachmetz Teligent, Inc. (856) 776-4632 www.teligent.com
GlobeNewswire · 10/22 16:25
Align Technology, Bio-Path Holdings leads healthcare gainers; InVivo Therapeutics, Teligent among major losers
Gainers: Align Technology (ALGN) +33%, Bio-Path Holdings (BPTH) +23%, Brainstorm Cell Therapeutics (BCLI) +13%, Beam Therapeutics (BEAM) +13%, Cardiff Oncology (CRDF) +10%.Losers: InVivo Therapeutics (NVIV) -45%, Teligent (TLGT) -27%, Aptinyx (APTX) -21%, Iterum Therapeutics (ITRM) -20%, Timber Pharmaceuticals (TMBR) -18%.
Seekingalpha · 10/22 15:04
Looking Into Teligent's Return On Capital Employed
During Q2, Teligent (NASDAQ: TLGT) brought in sales totaling $13.59 million. However, earnings decreased 75.81%, resulting in a loss of $4.37 million. In Q1, Teligent brought in $7.45 million in sales but lost $18.05 million in earnings.Why ROCE Is Significant Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company's ROCE. A higher ROCE is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROCE suggests the opposite. In Q2, Teligent posted an ROCE of 0.12%.Keep in mind, while ROCE is a good measure of a company's recent performance, it is not a highly reliable predictor of a company's earnings or sales in the near future.View more earnings on TLGTROCE is an important metric for the comparison of similar companies. A relatively high ROCE shows Teligent is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of capital, some of that money can be reinvested in more capital which will generally lead to higher returns and earnings per share growth.In Teligent's case, the positive ROCE ratio will be something investors pay attention to before making long-term financial decisions.Q2 Earnings Recap Teligent reported Q2 earnings per share at $-1.54/share, which beat analyst predictions of $-1.7/share.See more from Benzinga * Options Trades For This Crazy Market: Get Benzinga Options to Follow High-Conviction Trade Ideas * 20 Healthcare Stocks Moving In Wednesday's Pre-Market Session * 4 Sectors Moving Lower In Wednesday's Regular Market Session(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga · 10/22 13:44
Teligent CFO departs, interim appointed
Teligent (TLGT) CFO Damian Finio will leave the company to pursue another career opportunity, effective September 14.Mr. Finio, will serve as interim CFO while the company conducts a search for a permanent
Seekingalpha · 09/17 12:33
Immunomedics, Cassava Sciences leads gainers pack, Nano-X Imaging, Teligent among major losers
Gainers: Immunomedics (IMMU) +101%, Cassava Sciences, (SAVA) +78%, Vaxart (VXRT) +28%, Mersana Therapeutics (MRSN) +17%, Venus Concept (VERO) +15%.Losers: Nano-X Imaging (NNOX) -14%, Teligent (TLGT) -12%, Mallinckrodt (MNK) -12%, Kala Pharmaceuticals (KALA) -12%, Co-Diagnostics (CODX) -11%.
Seekingalpha · 09/14 15:06
Odonate Therapeutics leads healthcare gainers on equity offering, Pro-Dex and Rhythm Pharmaceuticals follow, Oncternal Therapeutics, Teligent and Stereotaxis among major losers
Gainers: Odonate Therapeutics (ODT) +22%, Pro-Dex (PDEX) +19%, Rhythm Pharmaceuticals (RYTM) +19%, Addex Therapeutics (ADDXF) +17%, Forte Biosciences (FBRX) +16%.Losers: Oncternal Therapeutics (ONCT) -15%, Teligent (TLGT) -9%, Stereotaxis (STXS) -7%, Viking Therapeutics (VKTX) -7%, VBI Vaccines (VBIV) -6%.
Seekingalpha · 08/28 15:01
INO, SRNE among premarket losers
Onconova Therapeutics (NASDAQ:ONTX) -71% after announcing topline results from Phase 3 INSPIRE trial. Northern Dynasty Minerals (NYSEMKT:NAK) -34% after Th
Seeking Alpha - Article · 08/24 12:27
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of TLGT. Analyze the recent business situations of Teligent Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average TLGT stock price target is 20.00 with a high estimate of 20.00 and a low estimate of 20.00.
EPS
Institutional Holdings
Institutions: 77
Institutional Holdings: 14.68M
% Owned: 272.36%
Shares Outstanding: 5.39M
TypeInstitutionsShares
Increased
2
7.78K
New
7
72.90K
Decreased
9
298.34K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.87%
Pharmaceuticals & Medical Research
-0.36%
Key Executives
Chairman/Director
John Celentano
President/Chief Executive Officer/Director
Timothy Sawyer
Secretary
Philip Yachmetz
Independent Director
Carole Ben-Maimon
Independent Director
Bhaskar Chaudhuri
Independent Director
Steven Koehler
Independent Director
Thomas Sabatino
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About TLGT
Teligent, Inc., formerly Igi Laboratories Inc, is a specialty generic pharmaceutical company. Under the Company's own label, it markets and sells generic injectable pharmaceutical products in the United States and Canada. In the United States it marketed 35 generic topical pharmaceutical products and four branded generic pharmaceutical products, as of December 31, 2018. It provides development, formulation and manufacturing services to the pharmaceutical, over-the-counter (OTC) and cosmetic industries. It focuses on developing, manufacturing and marketing a portfolio of generic pharmaceutical products under its own label in topical, injectable, complex and ophthalmic dosage forms, and managing its contract manufacturing and formulation services business. Its pipeline included 20 Abbreviated New Drug Application (ANDAs) filed with the United States Food and Drug Administration (FDA) for additional pharmaceutical products, as of December 31, 2018.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Teligent Inc (NEW JERSEY) stock information, including NASDAQ:TLGT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TLGT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TLGT stock methods without spending real money on the virtual paper trading platform.